National Institute for Health and Care Excellence

# Kidney cancer

**Stakeholder engagement – deadline for comments** 5pm on 21/02/24

**email**:[QualityStandards@nice.org.uk](mailto:QualityStandards@nice.org.uk)

Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly or arrive after the deadline.

# Introduction

NICE quality standards describe key areas for quality improvement in health, public health and social care. Each quality standard contains a set of quality statements with related measures. Quality statements are derived from evidence-based guidance, such as NICE guidance or NICE-accredited guidance. They are developed independently by NICE, in collaboration with health, public health and social care practitioners, their partners and people using services.

This quality standard covers the diagnosis and management of kidney cancer in adults. The key potential development source for this quality standard is the [NICE guideline on kidney cancer](https://www.nice.org.uk/guidance/indevelopment/gid-ng10398) (in development). The quality standard is being developed alongside the guideline and they will be published together.

Use the form to tell us:

* **What are the** **key areas for quality improvement** that you would want to see covered by this quality standard? **Please prioritise up to 5 areas** which you consider as having the greatest potential to improve the quality of care. Please state the specific aspects of care or service delivery that should be addressed, including the actions that you feel would most improve quality and the population group that should benefit.

# Organisation details

|  |  |
| --- | --- |
| **Organisation name – Stakeholder or respondent**  (if you are responding as an individual rather than a registered stakeholder please leave blank) |  |
| **Disclosure**  Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry. |  |
| **Name of person completing form** |  |
| **Supporting the quality standard**  Would your organisation like to express an interest in formally supporting this quality standard? [More information.](https://www.nice.org.uk/standards-and-indicators/get-involved/support-a-quality-standard) |  |
| **Type** | **[Office use only]** |

# Quality improvement comments

Type directly into this table. Don’t paste other tables into this table as your comments could get lost.

|  |  |  |
| --- | --- | --- |
| **Key area for quality improvement** | **Why is this a key area for quality improvement?** | **Data sources** |
| Separately list each of the 5 key areas for quality improvement that you would want to see covered by this quality standard | Evidence of information that care in the suggested key areas for quality improvement is poor or variable and requires improvement. Please include any evidence of inequalities and health inequalities in the suggested key areas for quality improvement. | As the quality statements must be measurable, please include any information on available data sources.  Information can include:   * National data sources that collect data relating to your suggested key areas for quality improvement * National audits * Other data sources |
| **Example:**  Structured education programmes for people with diabetes following diagnosis. | **Example:** The National Diabetes Audit highlighted that people with type 1 diabetes were less likely than those with type 2 diabetes to be offered a structured education programme within 12 months of diagnosis. There is considerable variation across different areas. The audit also highlighted poor recording of attendance within primary care systems. It is important to ensure that the delivery of structured education programmes is tailored to meet individual needs. | **Example:** Please see NHS Digital’s national diabetes audit which highlights findings of data collection from primary and secondary care relating to structured education programmes.  <https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit> |
| Key area for quality improvement 1 |  |  |
| Key area for quality improvement 2 |  |  |
| Key area for quality improvement 3 |  |  |
| Key area for quality improvement 4 |  |  |
| Key area for quality improvement 5 |  |  |

# Checklist for submitting comments

* Use this form and submit it as a Word document (not a PDF).
* Complete the disclosure about links with, or funding from, the tobacco industry.
* Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
* Do not paste other tables into this table – type directly into the table.
* **Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.**
* Do not include medical information about yourself or another person from which you or the person could be identified.
* Spell out any abbreviations you use
* Please provide concise supporting information for each key area. Provide reference to examples from the published or grey literature such as national, regional or local reports of variation in care, audits, surveys, confidential enquiries, uptake reports and evaluations such as impact of NICE guidance recommendations
* For copyright reasons, do not include attachments of **published** material such as research articles, letters or leaflets. However, if you give us the full citation, we will obtain our own copy
* Attachments of unpublished reports, local reports / documents are permissible. If you wish to provide academic in confidence material i.e. written but not yet published, or commercial in confidence i.e. internal documentation, highlight this using the highlighter function in Word.

Please return to [QualityStandards@nice.org.uk](mailto:QualityStandards@nice.org.uk)

NICE reserves the right to summarise and edit comments received during consultations, or not to publish them at all, where in the reasonable opinion of NICE, the comments are voluminous, publication would be unlawful or publication would be otherwise inappropriate.

Comments received from registered stakeholders and respondents during our stakeholder engagements are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.